PL2470546T3 - Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR - Google Patents

Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR

Info

Publication number
PL2470546T3
PL2470546T3 PL10749736T PL10749736T PL2470546T3 PL 2470546 T3 PL2470546 T3 PL 2470546T3 PL 10749736 T PL10749736 T PL 10749736T PL 10749736 T PL10749736 T PL 10749736T PL 2470546 T3 PL2470546 T3 PL 2470546T3
Authority
PL
Poland
Prior art keywords
hexahydrooxazinopteridine
compounds
mtor inhibitors
mtor
inhibitors
Prior art date
Application number
PL10749736T
Other languages
English (en)
Inventor
Nicholas Scorah
Bohan Jin
Qing Dong
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PL2470546T3 publication Critical patent/PL2470546T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PL10749736T 2009-08-28 2010-08-26 Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR PL2470546T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23806409P 2009-08-28 2009-08-28
US31360810P 2010-03-12 2010-03-12
EP10749736.4A EP2470546B1 (en) 2009-08-28 2010-08-26 Hexahydrooxazinopteridine compounds for use as mtor inhibitors
PCT/US2010/046839 WO2011025889A1 (en) 2009-08-28 2010-08-26 HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS

Publications (1)

Publication Number Publication Date
PL2470546T3 true PL2470546T3 (pl) 2013-12-31

Family

ID=42768136

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10749736T PL2470546T3 (pl) 2009-08-28 2010-08-26 Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR

Country Status (13)

Country Link
US (2) US8163755B2 (pl)
EP (1) EP2470546B1 (pl)
JP (1) JP2013503183A (pl)
AR (1) AR077974A1 (pl)
DK (1) DK2470546T3 (pl)
ES (1) ES2432315T3 (pl)
HR (1) HRP20130951T1 (pl)
PL (1) PL2470546T3 (pl)
PT (1) PT2470546E (pl)
SI (1) SI2470546T1 (pl)
TW (1) TW201119656A (pl)
UY (1) UY32863A (pl)
WO (1) WO2011025889A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940752B2 (en) 2009-06-29 2015-01-27 Incyte Corporation Pyrimidinones as PI3K inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011079118A1 (en) * 2009-12-23 2011-06-30 Elan Pharmaceuticals, Inc Pteridinones as inhibitors of polo-like kinase
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
UY33883A (es) 2011-01-31 2012-08-31 Novartis Ag Novedosos derivados heterocíclicos
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US8791107B2 (en) * 2011-02-25 2014-07-29 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
CA2846652C (en) 2011-09-02 2019-11-05 Incyte Corporation Heterocyclylamines as pi3k inhibitors
MX340452B (es) 2011-10-28 2016-07-08 Novartis Ag Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
SG10201805807PA (en) 2012-06-26 2018-08-30 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2014037480A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
EP3024457A4 (en) 2013-07-26 2017-06-28 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
CN105636962B (zh) * 2013-10-15 2017-10-13 靳博涵 新型化合物、用途及其制备方法
EA201692011A1 (ru) 2014-04-08 2017-01-30 Инсайт Корпорейшн Лечение b-клеточных злокачественных новообразований с применением комбинации ингибиторов jak и pi3k
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MY187502A (en) 2015-02-27 2021-09-24 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US20160362424A1 (en) 2015-05-11 2016-12-15 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
KR102017676B1 (ko) * 2018-03-09 2019-09-03 연세대학교 원주산학협력단 익상편 예방 및 치료용 조성물
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076440A1 (en) 2002-03-06 2003-09-18 Smithkline Beecham Corporation Condensed heterocyclic compounds as calcitonin agonists
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
US8911498B2 (en) 2005-02-10 2014-12-16 DePuy Synthes Products, LLC Intervertebral prosthetic disc
ES2319461T3 (es) 2005-02-10 2009-05-07 Bristol-Myers Squibb Company Dihidroquinazolinonas como moduladores de 5ht.
EP2057129A1 (en) 2006-08-24 2009-05-13 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
BRPI0817806A2 (pt) 2007-10-05 2014-10-07 Cylene Pharmaceuticals Inc Análogos de quinolona e métodos relacionados a estes
WO2009070524A1 (en) * 2007-11-27 2009-06-04 Wyeth Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors
US20120115848A1 (en) * 2010-10-08 2012-05-10 Elan Pharmaceuticals, Inc. Inhibitors of Polo-Like Kinase

Also Published As

Publication number Publication date
US20110053921A1 (en) 2011-03-03
AR077974A1 (es) 2011-10-05
EP2470546B1 (en) 2013-07-24
ES2432315T3 (es) 2013-12-02
US8268819B2 (en) 2012-09-18
TW201119656A (en) 2011-06-16
EP2470546A1 (en) 2012-07-04
HRP20130951T1 (hr) 2013-11-22
UY32863A (es) 2011-03-31
PT2470546E (pt) 2013-10-14
US20120178924A1 (en) 2012-07-12
WO2011025889A1 (en) 2011-03-03
US8163755B2 (en) 2012-04-24
SI2470546T1 (sl) 2013-12-31
JP2013503183A (ja) 2013-01-31
DK2470546T3 (da) 2013-10-14

Similar Documents

Publication Publication Date Title
SI2470546T1 (sl) Spojine heksahidrooksazinopteridina za uporabo kot MTOR inhibitorji
HK1218758A1 (zh) 作為 激酶抑制劑的化合物
IL216145A0 (en) Dihydropyrimidinones for use as bace2 inhibitors
HK1197233A1 (en) Synthetic methods for spiro-oxindole compounds
IL215297A0 (en) Imidazopyrazines for use as kinase inhibitors
GB0906472D0 (en) New compounds
GB0906470D0 (en) New compounds
IL220154A0 (en) Novel pyrimidine compounds as mtor and pi3k inhibitors
ZA201206410B (en) Polyheterocylic compounds highly potent as hcv inhibitors
GB0907425D0 (en) Compounds
EP2393493A4 (en) LINKS
ZA201400374B (en) 4-piperidinyl compounds for use as tankyrase inhibitors
EP2491025A4 (en) AZA-AZULENE COMPOUNDS
EP2416657A4 (en) COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
ZA201108131B (en) Dihydroorotate- dehydrogenasee inhibitors as virostatic compounds
EP2519508A4 (en) METALLO ENZYME INHIBITOR COMPOUNDS
IL220701A0 (en) Tricyclic compounds for use as kinase inhibitors
GB0903493D0 (en) New compounds
GB0900388D0 (en) New compounds
GB201004372D0 (en) Compounds for purification
AP2909A (en) Pyrazinoisoquinoline Compounds
EP2443115A4 (en) COMPOUNDS
GB201004308D0 (en) New inhibitor compounds
GB0914441D0 (en) Compound for therapy
GB0903080D0 (en) Compound for therapy